gutflix
GI learning, personalised

Summary

# CORTICOSTEROID-FREE EFFICACY OUTCOMES IN PATIENTS RECEIVING CONCOMITANT CORTICOSTEROIDS AT BASELINE IN THE ETRASIMOD ELEVATE UC 52 TRIAL

Yvette Leung

UEG Week Copenhagen 2023 | Poster

IBD

October 17, 2023

**In a post hoc analysis of ELEVATE UC 52, etrasimod 2 mg once daily demonstrated superior corticosteroid-free efficacy versus placebo at Week 52 in ulcerative colitis patients receiving baseline corticosteroids, with no notable negative safety impact from concomitant corticosteroid use.**

## KEY POINTS

- Among patients on baseline corticosteroids, significantly more etrasimod versus placebo patients achieved 12-week corticosteroid-free clinical remission at Week 52 (31.2% vs 7.1%, adjusted difference 23.2%, p=0.0003).
- Etrasimod showed superior corticosteroid-free endoscopic improvement at Week 52 (37.6% vs 19.0%, p=0.0226) and CR at Week 12 plus corticosteroid-free CR at Week 52 (19.4% vs 4.8%, p=0.0092).
- Four-week corticosteroid-free symptomatic remission was significantly higher with etrasimod versus placebo from Week 40 onwards (differences 16.6-26.6%, p<0.05).
- Age per 10-year increase was significantly associated with achieving 12-week corticosteroid-free clinical remission at Week 52 (OR 1.51, p=0.04), while biologic/JAK inhibitor-naïve status was not (p=0.07).
- In patients on baseline corticosteroids, etrasimod had slightly more adverse events (71.0% vs 61.9%) but fewer serious adverse events (6.5% vs 14.3%) and serious infections (0% vs 7.1%) than placebo.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/7fcd5374-743b-11ee-86d1-0242ac140004

**AI-generated summary**

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.